ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1734

A Phase Ib Clinical Trial With Dekavil (F8-IL10), An Immunoregulatory ‘Armed Antibody’ For The Treatment Of Rheumatoid Arthritis, Used In Combination With Methotrexate

M. Galeazzi1, L Bazzichi2, E Prisco3, G D Sebastiani4, D. Neri5, L Giovannoni6, F Bacchion7, M Bardelli1, C Baldi1, E Selvi1, G Minisola8, R Caporali9 and S Bombardieri10, 1Rheumatology Unit, University Hospital of Siena, Siena, Siena, Italy, 2Division of Rheumatology, University of Pisa, Pisa, Pisa, Italy, 3Rheumatology, Deptartment of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, 4Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 5Chemistry and Applied Sciences, Swiss Federal Institute of Technology, Zurich, Zurich, Switzerland, 6Clinical Research Unit, Philogen S.p.A., Siena, Sovicille - (SI), Italy, 7Clinical Research Unit, Philogen S.p.A, Siena, Sovicille - (SI), Italy, 8Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, 9Department of Rheumatology, University of Pavia, IRCSS Policlinico San Matteo Foundation, Pavia, Pavia, Italy, 10Department of Clinical and Experimental Medicine, Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities

Session Type: Abstract Submissions (ACR)

Background/Purpose: A therapeutic strategy based on the selective delivery of an immuno-regulatory cytokine to the sites of inflammatory disease has been developed. DEKAVIL is an ‘armed antibody’, composed of the human F8 antibody (specific to the EDA domain of fibronectin, a marker of angiogenesis) fused to the human anti-inflammatory cytokine interleukin-10 (IL10), enabling delivery and accumulation of the cytokine specifically at sites of disease. This ‘targeting’ approach increases the therapeutic index of IL10. A Phase Ib clinical trial is now on-going, which features the administration of weekly doses of DEKAVIL, in combination with MTX, to patients with RA who have previously failed at least one line of anti-TNF therapy. Objectives of the study are to establish the MTD, safety and tolerability, to obtain preliminary information on efficacy and to assess the PK behavior. Here, we report the results obtained in 14 patients studied to date.

Methods: Cohorts of 3-6 patients with active RA were assigned to receive escalating doses of DEKAVIL (6, 15, 30, 60, 110, 160 and 210 µg/kg respectively) in combination with 15mg of MTX. The treatment is given as once weekly sc injection for up to 8 weeks. Standard safety evaluations performed on days 1 through 28 were used to determine the dose limiting toxicity. Response was assessed after 4 and 8 weeks of treatment according to ACR and EULAR (DAS28) criteria. The PK profile and formation of human anti-fusion protein antibodies are measured using standard methods.

Results: Responses are summarized in the attached table. All 3 patients in the first cohort (6 μg/kg) achieved ACR 50 response, accompanied by a ‘good’ EULAR response. In cohort 2 (15 μg/kg), patient 5 enjoyed an ACR 70 response, whereas patients 4 and 6 did not reach ACR20 despite achieving ‘moderate’ EULAR response. In cohort 3 (30 μg/kg) patient 8 achieved an ACR70. This was particularly striking as it was prolonged and at a late evaluation time point. Patient 7 did not achieve any ACR response, and patient 9 achieved an ACR20 response. In cohort 4 (60 μg/kg) Patient 11 achieved an ACR50 at EOT, which improved to an ACR70 response at a late evaluation time point, demonstrating an extended response period. Patient 10 achieved an ACR20 and patients 12 and 13 did not respond. In cohort 5 (110 μg/kg) patient 14 achieved an ACR20 at week 5. Trends of swollen/tender joints and DAS28 score also showed improvement. Excellent tolerability was observed, since no grade >2 adverse drug reactions were reported. A very low signal from human anti-fusion protein antibodies was occasionally detected. Several patients are still being treated and followed-up.

Conclusion: The promising safety data, together with preliminary positive signs of activity, suggest that the targeted delivery of IL10 to the site of inflammation may be beneficial to patients with RA. The extended activity periods indicate the possibility for a long lasting therapeutic potential.


Disclosure:

M. Galeazzi,
None;

L. Bazzichi,
None;

E. Prisco,
None;

G. D. Sebastiani,
None;

D. Neri,

Dario Neri,

1;

L. Giovannoni,

L Giovannoni,

3;

F. Bacchion,

F Bacchion,

3;

M. Bardelli,
None;

C. Baldi,
None;

E. Selvi,
None;

G. Minisola,
None;

R. Caporali,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-ib-clinical-trial-with-dekavil-f8-il10-an-immunoregulatory-armed-antibody-for-the-treatment-of-rheumatoid-arthritis-used-in-combination-with-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences